Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence.
about
Developing and applying the adverse outcome pathway concept for understanding and predicting neurotoxicityRecommended approaches to the scientific evaluation of ecotoxicological hazards and risks of endocrine-active substances.Accelerating Adverse Outcome Pathway Development Using Publicly Available Data Sources.Programmed Effects in Neurobehavior and Antioxidative Physiology in Zebrafish Embryonically Exposed to Cadmium: Observations and Hypothesized Adverse Outcome Pathway Framework.Transcriptomic responses in the oral cavity of F344 rats and B6C3F1 mice following exposure to Cr(VI): Implications for risk assessment.How Adverse Outcome Pathways Can Aid the Development and Use of Computational Prediction Models for Regulatory Toxicology.Adverse Outcome Pathways for Regulatory Applications: Examination of Four Case Studies With Different Degrees of Completeness and Scientific Confidence.The adverse outcome pathway (AOP) for chemical binding to tubulin in oocytes leading to aneuploid offspring.Predicting organ toxicity using in vitro bioactivity data and chemical structure.Advancing the adverse outcome pathway framework-An international horizon scanning approach.Evolution of chemical-specific adjustment factors (CSAF) based on recent international experience; increasing utility and facilitating regulatory acceptance.A comprehensive review of regulatory test methods for endocrine adverse health effects.Ecdysone Receptor Agonism Leading to Lethal Molting Disruption in Arthropods: Review and Adverse Outcome Pathway Development.In vitro acute and developmental neurotoxicity screening: an overview of cellular platforms and high-throughput technical possibilities.Cigarette Filter Ventilation and its Relationship to Increasing Rates of Lung Adenocarcinoma.Characterizing "Adversity" of Pathology Findings in Nonclinical Toxicity Studies: Results from the 4th ESTP International Expert Workshop.Derivation and Evaluation of Putative Adverse Outcome Pathways for the Effects of Cyclooxygenase Inhibitors on Reproductive Processes in Female Fish.Practical approaches to adverse outcome pathway development and weight-of-evidence evaluation as illustrated by ecotoxicological case studies.Quantitative weight-of-evidence analysis of the persistence, bioaccumulation, toxicity, and potential for long-range transport of the cyclic volatile methyl siloxanes.Systems Biology to Support Nanomaterial Grouping.Challenges in assigning endocrine-specific modes of action: Recommendations for researchers and regulators.Weight of evidence evaluation of a network of adverse outcome pathways linking activation of the nicotinic acetylcholine receptor in honey bees to colony death.Current limitations and recommendations to improve testing for the environmental assessment of endocrine active substances.Adverse outcome pathways: Application to enhance mechanistic understanding of neurotoxicity.Stat-6 signaling pathway and not Interleukin-1 mediates multi-walled carbon nanotube-induced lung fibrosis in mice: insights from an adverse outcome pathway framework.Adverse outcome pathways: opportunities, limitations and open questionsComparison of Toxicity and Recovery in the Duodenum of B6C3F1 Mice Following Treatment with Intestinal Carcinogens Captan, Folpet, and Hexavalent Chromium.Guidance on the use of the weight of evidence approach in scientific assessmentsDecision tree models to classify nanomaterials according to the DF4nanoGrouping scheme.Quantitative Adverse Outcome Pathways and Their Application to Predictive Toxicology.Integration of mechanistic and pharmacokinetic information to derive oral reference dose and margin-of-exposure values for hexavalent chromium.Application of Adverse Outcome Pathways to U.S. EPA's Endocrine Disruptor Screening Program.Adverse outcome pathways: a concise introduction for toxicologists.Development of the Adverse Outcome Pathway (AOP): Chronic binding of antagonist to N-methyl-d-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities of children.Adverse Outcome Pathway Networks II: Network Analytics.The future trajectory of adverse outcome pathways: a commentary.Harvesting the promise of AOPs: An assessment and recommendations
P2860
Q28394433-BC03CA1B-63DB-4639-AABE-BBE890396F4DQ31157278-A55DD0DF-3233-405A-846C-3943BF11D6C7Q35904173-C50A3C1C-5B00-46FF-A7F7-087D6FA7C42CQ37465469-06CAB5B3-F76C-483A-9F02-0FAB877F8CC7Q37561128-9BD6DCA5-71AB-4FD0-AAE2-116C4AECC616Q37684551-6D667E9F-5925-48EC-A652-DDF8F505855BQ38616250-D254C4F4-AC45-427D-96BD-71A0E0F9EB30Q38637834-7C461F42-8D98-48A5-AB04-DD290B049BDFQ38646520-4C4FBC88-4B7E-4067-A4C5-F06364EE632AQ38679066-79217D6A-4EF4-4096-A295-B9B112253DECQ38691542-0875939A-C6DA-4E2A-8677-15EADEAA4725Q38724654-569A25FC-EA7A-4994-B519-AAF12F8C9CF4Q38738140-F3574654-B6CF-41AE-8CDC-B32F6481BB6AQ38753758-22520D8C-5F5E-43D5-953A-55E6B8B5FB01Q38774196-B03104E2-A304-4998-8885-55BCF74514D8Q38814376-5D5B96A6-8CD0-4C6A-9298-7AD8D2A797B0Q38959910-45A582E6-3064-4D8C-97EC-25E37BD87D43Q38960807-D2A165FA-9C35-42C8-B3A6-CDB365146C10Q38961470-078F630F-7C8E-44D3-9A10-B978C968779DQ38974885-5E4C7F77-8CA6-4068-8405-0F5DC1813D8EQ39099271-0E8529B3-8FF9-4B0B-9E69-2C9BF0EEC16FQ39105285-7B31BB7E-BC98-4E4C-8F71-ACC67D072338Q39239547-FE6F763B-F743-4938-B716-8B2A036BE9F5Q39320908-24493807-3CD5-46F4-8526-BE7CF580D3EAQ41107325-5A7BDA75-5BB7-41D7-9291-E2AEAA991DECQ42307037-C7F63BEA-52F5-4B72-BA29-85E361ADBDD8Q45073582-1DBEAAD9-6DCA-40A1-A8A2-C2FFF9E04E08Q47160449-42E3E767-ED31-4B2B-9F97-0CBEDA534498Q47282095-68238777-4BA9-4583-9259-6C2D15464DB1Q47353535-5C3C11E2-1370-4D30-A517-09435948968CQ47731428-022960F3-3B11-478D-A600-E19D8CD75F44Q47947469-915AB092-5501-479A-AB37-914F17339CCDQ49800221-54E5FD03-6183-40C0-A832-D91C6C63DD6EQ50420073-31E05AC7-38BD-47C0-9F94-E02EB218BBD3Q51150402-4008A31C-240E-4CD5-99ED-E0B83CC67FC7Q51739072-475B2F91-DAAB-4862-8348-E3A54DB92ABEQ57178963-1FEF0AA0-CA0E-4A0E-8DD5-DA1401B16755
P2860
Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Increasing Scientific Confiden ...... Evaluating Weight of Evidence.
@en
Increasing Scientific Confiden ...... Evaluating Weight of Evidence.
@nl
type
label
Increasing Scientific Confiden ...... Evaluating Weight of Evidence.
@en
Increasing Scientific Confiden ...... Evaluating Weight of Evidence.
@nl
prefLabel
Increasing Scientific Confiden ...... Evaluating Weight of Evidence.
@en
Increasing Scientific Confiden ...... Evaluating Weight of Evidence.
@nl
P2093
P1476
Increasing Scientific Confiden ...... Evaluating Weight of Evidence.
@en
P2093
Bart Van Der Burg
Bette Meek
Daniel L Villeneuve
Gerald T Ankley
Haruna Watanabe
Igor Linkov
Magdalini Sachana
Richard A Becker
Sean W Kennedy
Stephen W Edwards
P304
P356
10.1016/J.YRTPH.2015.04.004
P407
P577
2015-04-08T00:00:00Z